Standards, Controls, Materials (e.g., Validation Studies, Buffer Systems, Etc.) Patents (Class 435/967)
  • Patent number: 10927293
    Abstract: Provided is a core-shell structured fluorescent complex comprising: a core portion comprising therein a polymer and a fluorescent material; and a shell portion including silica or alumina covering at least a part of a surface of the core portion, wherein the fluorescent material is included in greater than or equal to 0.01 parts by weight and less than or equal to 50 parts by weight with respect to 100 parts by weight of the polymer, and wherein the polymer is an ionic polymer or ionic polymer resin and has a weight average molecular weight of greater than or equal to 1,000 and less than or equal to 300,000, a light conversion film including the core-shell structured fluorescent complex, and an electronic device including the same.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: February 23, 2021
    Assignee: LG CHEM, LTD.
    Inventors: Du Hyeon Shin, Youkyong Seo
  • Patent number: 8865470
    Abstract: The present invention reagents and methods for setting up an instruments having a multiplicity of detector channels for analyzing a multiplicity of fluorescent dyes. The present invention is particularly applicable in the field of flow cytometry.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: October 21, 2014
    Assignee: Becton, Dickinson and Company
    Inventors: Ming Yan, Alan M. Stall, Joseph T. Trotter, Robert A. Hoffman
  • Patent number: 8822230
    Abstract: In a chromatography quantitative measuring apparatus according to the present invention, a beam applied from a light source to a chromatography test strip is formed into an elliptical shape by an optical means such as a cylindrical lens, a variation in absorbance that accompanies elution of a marker regent is detected while the elliptical beam is applied between a marker reagent hold part and a detection part, and a measurement is automatically started in a prescribed period of time since the detection of variation. According to the chromatography quantitative measuring apparatus so configured, non-uniform coloration is reduced by shaping the beam elliptically with the optical means, whereby the accuracy of quantitative analysis is enhanced, and the apparatus can be operated easily.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: September 2, 2014
    Assignee: Panasonic Healthcare Co., Ltd.
    Inventors: Koji Miyoshi, Masahiro Aga, Kaoru Shigematsu
  • Patent number: 8802389
    Abstract: The subject invention relates in part to the surprising and unexpected discovery that insects that are resistant to Bacillus thuringiensis Cry toxins have measurably altered alkaline phosphatase (ALP) activity as compared to insects that are susceptible to Cry toxins. This and other surprising discoveries reported herein have broad implications in areas such as managing and monitoring the development of insect resistance to B.t. toxins. For example, the subject invention provides a simple and fast assay (enzymatic or otherwise) for detecting ALP activity levels and thereby monitoring the development of resistance by insects to crystal protein insect toxins. There was no prior motivation or suggestion to go about resistance monitoring using this simple and easy approach.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: August 12, 2014
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: Michael J. Adang, Rebecca McNall, Juan Luis Jurat Fuentes
  • Patent number: 8778698
    Abstract: In a chromatography quantitative measuring apparatus, a beam applied from a light source to a chromatography test strip is formed into an elliptical shape by an optical means such as a cylindrical lens, a variation in absorbance that accompanies elution of a marker regent is detected while the elliptical beam is applied between a marker reagent hold part and a detection part, and a measurement is automatically started in a prescribed period of time since the detection of variation. According to the chromatography quantitative measuring apparatus so configured, non-uniform coloration is reduced by shaping the beam elliptically with the optical means, whereby the accuracy of quantitative analysis is enhanced, and the apparatus can be operated easily.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: July 15, 2014
    Assignee: Panasonic Healthcare Co., Ltd.
    Inventors: Koji Miyoshi, Masahiro Aga, Kaoru Shigematsu
  • Patent number: 8697373
    Abstract: Methods and reagents for classifying HER2+ breast tumors and for identifying new HER2+ breast tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of HER2+ breast cancer.
    Type: Grant
    Filed: October 9, 2007
    Date of Patent: April 15, 2014
    Assignee: Clarient Diagnostic Services, Inc.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz
  • Patent number: 8628931
    Abstract: This invention relates, e.g., to a method for predicting a subject's response to a chemotherapeutic agent and/or the subject's prognosis, comprising measuring the phosphorylation state of at least one member of the mTOR pathway, and/or of at least one member of an interconnected polypeptide pathway (e.g. a member of the Akt pathway or a member of the IRS pathway), compared to a baseline value, in a cancer tissue or cancer cell sample from the subject, wherein an elevated level of the phosphorylation state compared to the baseline value indicates that the subject is a non-responder to the chemotherapeutic agent and/or has a poor prognosis. Also described is a method for treating a cancer in a subject in need thereof, wherein the subject exhibits an elevated level of the phosphorylation state, comprising administering one or more inhibitors of the mTOR and/or an interconnected pathway.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: January 14, 2014
    Assignee: George Mason Intellectual Properties, Inc.
    Inventors: Lance A. Liotta, Emanuel F. Petricoin, III, Virginia Espina
  • Patent number: 8512960
    Abstract: This invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expression or action. Antagonists to an 88 KDa autocrine growth and tumorigenicity stimulator are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: August 20, 2013
    Assignee: A&G Pharmaceutical, Inc.
    Inventor: Ginette Serrero
  • Patent number: 8415161
    Abstract: The present invention reagents and methods for setting up an instruments having a multiplicity of detector channels for analyzing a multiplicity of fluorescent dyes. The present invention is particularly applicable in the field of flow cytometry.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: April 9, 2013
    Assignee: Becton, Dickinson and Company
    Inventors: Ming Yan, Alan M. Stall, Joseph T. Trotter, Robert A. Hoffman
  • Patent number: 8383410
    Abstract: The invention concerns an internal standard used to quantitative analysis of the risk of humoral (i.e. vascular) transplant rejection. The internal standard consists of a stable composition of the C4d complement bound to a carrier consisting of erythrocytes or microparticles. The invention also concerns a method for analyzing in vitro the risk of humoral organ transplant rejection, which consists in determining the amount of component of C4d component fixed on the erythrocytes contained in a blood sample from a patient.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: February 26, 2013
    Assignee: Universite de Reims Champagne-Ardenne
    Inventors: Jacques Henri Max Cohen, Brigitte Reveil, Aymric Kisserli, Fadi Haidar, Béatrice Donvito
  • Patent number: 8309366
    Abstract: Methods and devices for rapid lateral flow immunoassays to detect specific antibodies within a liquid sample while also validating the adequacy of the liquid sample for the presence of immunoglobulin and the integrity and immunoreactivity of the test reagents that detect the antibodies of interest, without requiring instrumentation. The methods and devices provide for delivery of a diluted liquid sample to a single location that simultaneously directs the liquid flow along two or more separate flow paths, one that serves as a positive control to confirm that all critical reagents of the test are immunoreactive, and that the sample being tested is adequate, and the other to detect specific antibodies if present.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: November 13, 2012
    Inventor: Thomas M. Buchanan
  • Patent number: 8114606
    Abstract: This invention provides antibodies immunologically specific for human ARL-1 (also referred to AKR1B10), a species of the aldo-keto reductase superfamily of proteins. The invention also provides methods of making and methods of using said antibodies.
    Type: Grant
    Filed: February 15, 2008
    Date of Patent: February 14, 2012
    Assignee: The Board of Trustees of Southern Illinois University
    Inventor: Deliang Cao
  • Patent number: 8039229
    Abstract: The subject invention relates in part to the surprising and unexpected discovery that insects that are resistant to Bacillus thuringiensis Cry toxins have measurably altered alkaline phosphatase (ALP) activity as compared to insects that are susceptible to Cry toxins. This and other surprising discoveries reported herein have broad implications in areas such as managing and monitoring the development of insect resistance to B.t. toxins. For example, the subject invention provides a simple and fast assay (enzymatic or otherwise) for detecting ALP activity levels and thereby monitoring the development of resistance by insects to crystal protein insect toxins. There was no prior motivation or suggestion to go about resistance monitoring using this simple and easy approach.
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: October 18, 2011
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: Michael J. Adang, Rebecca McNall, Juan Luis Jurat Fuentes
  • Patent number: 7981667
    Abstract: An alloyed semiconductor quantum dot comprising an alloy of at least two semiconductors, wherein the quantum dot has a homogeneous composition and is characterized by a band gap energy that is non-linearly related to the molar ratio of the at least two semiconductors; a series of alloyed semiconductor quantum dots related thereto; a concentration-gradient quantum dot comprising an alloy of a first semiconductor and a second semiconductor, wherein the concentration of the first semiconductor gradually increases from the core of the quantum dot to the surface of the quantum dot and the concentration of the second semiconductor gradually decreases from the core of the quantum dot to the surface of the quantum dot; a series of concentration-gradient quantum dots related thereto; in vitro and in vivo methods of use; and methods of producing the alloyed semiconductor and concentration-gradient quantum dots and the series of quantum dots related thereto.
    Type: Grant
    Filed: April 28, 2004
    Date of Patent: July 19, 2011
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Shuming Nie, Robert E. Bailey
  • Patent number: 7910381
    Abstract: A chromatographic specific binding assay strip device, comprising: a non-permeable platform strip; a permeable membrane testing strip positioned on top of said non-permeable platform strip, with the testing strip comprising at least one capture reagent site containing a capture reagent for at least one specific analyte, a sample receiving pad positioned on top of and at a proximal end of the non-permeable platform strip, with the sample receiving pad having contact with a proximal end of said permeable membrane testing strip, a reservoir pad positioned on top of and at a distal end of said non-permeable membrane testing strip, with the reservoir pad having contact with a proximal end of said permeable membrane test strip; a supporting strip attached to and extending from the proximal end of said non-permeable platform strip; and a conjugate pad positioned on said supporting strip, said conjugate pad comprising a semi-permeable membrane containing a colorant conjugate.
    Type: Grant
    Filed: March 5, 2008
    Date of Patent: March 22, 2011
    Assignee: BioAssay Works
    Inventors: Glen Ford, Leslie Kirkegaard
  • Patent number: 7785109
    Abstract: A method for monitoring cleaning of a surface includes applying an amount of transparent indicator material to an area of a surface and measuring the amount of transparent indicator material remaining on the surface. The transparent indicator material may be fixed on the surface by drying and, when a fluorescent material, may be measured through exposure to ultraviolet radiation.
    Type: Grant
    Filed: June 12, 2009
    Date of Patent: August 31, 2010
    Assignee: Kleancheck Systems, LLC
    Inventor: Philip C. Carling
  • Patent number: 7785822
    Abstract: The present invention provides methods for the detection of biliverdin in birds (avian species) and reptiles.
    Type: Grant
    Filed: August 27, 2003
    Date of Patent: August 31, 2010
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: Christopher Gregory, Branson W. Ritchie
  • Patent number: 7780453
    Abstract: A method for monitoring cleaning of a surface includes applying an amount of transparent indicator material to an area of a surface and measuring the amount of transparent indicator material remaining on the surface. The transparent indicator material may be fixed on the surface by drying and, when a fluorescent material, may be measured through exposure to ultraviolet radiation.
    Type: Grant
    Filed: June 12, 2009
    Date of Patent: August 24, 2010
    Assignee: Kleancheck Systems, LLC
    Inventor: Philip C. Carling
  • Patent number: 7722858
    Abstract: The present invention provides a method of determining whether an individual is at risk for atherosclerosis, comprising the step of measuring the level of cLDL and/or autoantibody to cLDL in a sample obtained from this individual. The invention further discloses a method of reducing carbamylation in an individual with a monomeric amino acid or other enzymatic or non-enzymatic inhibitors of carbamylation. The instant invention also provides a method to decrease the level of cLDL by direct elimination of cLDL from the blood or plasma of an individual. The invention also provides a method of treating or preventing atherosclerosis in an individual by inhibiting aggregation and/or deposition of cLDL in the individual.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: May 25, 2010
    Assignees: Board of Trustees of the University of Arkansas, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Sudhir V. Shah, Alexei G. Basnakian, Yousri M. Barri
  • Patent number: 7695973
    Abstract: The present invention provides methods for quantitation of glycated protein in a biological sample using a solid support matrix by making a first bound protein measurement total bound protein under conditions where both glycated and non-glycated protein bind to the support in making a second bound protein measurement under conditions where glycated protein is bound to the support and non-glycated protein is not substantially bound. Diagnostic devices and kits comprising the methods of the present invention are also provided.
    Type: Grant
    Filed: February 7, 2007
    Date of Patent: April 13, 2010
    Assignee: Scripps Laboratories, Inc.
    Inventors: Ralph P. McCroskey, Cameron E. Melton
  • Patent number: 7674623
    Abstract: The present invention relates to methods for making stable test samples that can be used in ligand-binding assays for measuring natriuretic peptides.
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: March 9, 2010
    Assignee: Abbott Laboratories, Inc.
    Inventors: Robert G. Parsons, David J. Daghfal, Cherie A. Lipowsky, Ray A. Weigand, Judith A. Friese
  • Patent number: 7638292
    Abstract: A method for detection and/or quantification of cardiac troponin I (cTnI) in a sample derived from an individual's blood, the method being based on a sandwich immunoassay employing at least two capture antibodies and at least one tracer antibody, in which a first capture antibody is directed to the N-terminal part of cTnI, to the C-terminal part of cTnI or to the part of the cTnI midfragment, which is slightly affected by the interfering factor, and a second capture antibody is directed to another of these parts, and a tracer antibody is directed to the N-terminal part of cTnI, to the C-terminal part of cTnI or to TnC, which is complexed with cTnI.
    Type: Grant
    Filed: November 13, 2007
    Date of Patent: December 29, 2009
    Assignee: University of Turku
    Inventors: Susann Eriksson, Kim Pettersson
  • Patent number: 7605003
    Abstract: The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject.
    Type: Grant
    Filed: August 5, 2003
    Date of Patent: October 20, 2009
    Assignees: The Johns Hopkins University, Vermillion, Inc.
    Inventors: Daniel W. Chan, Zhen Zhang, Eric Fung, Xiao-Ying Meng
  • Patent number: 7604952
    Abstract: A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient.
    Type: Grant
    Filed: January 16, 2007
    Date of Patent: October 20, 2009
    Assignee: Leuven Research & Development VZW
    Inventors: Paul N. Holvoet, Désiré J. Collen
  • Patent number: 7588905
    Abstract: A method for identifying or monitoring SLE in an individual is provided. The method includes quantitating complement component C4d on the surfaces of platelets and comparing the amounts of C4d to reference levels of C4d on platelets of individuals without SLE and/or on platelets of the individual obtained at a different time. Kits for use in the above-described methods are provided along with computer readable media tangibly embodying executable instructions to perform the methods.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: September 15, 2009
    Assignee: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Joseph M. Ahearn, Susan M. Manzi, Jeannine Navratil
  • Patent number: 7585640
    Abstract: The invention is related to methods of diagnosing inflammatory diseases or conditions by determining levels of components of the complement pathway on the surface of white blood cells.
    Type: Grant
    Filed: May 11, 2005
    Date of Patent: September 8, 2009
    Assignee: University of Pittsburgh
    Inventors: Joseph M. Ahearn, Susan M. Manzi, Chau-Ching Liu
  • Patent number: 7476551
    Abstract: The present invention provides a method of determining whether an individual is at risk for atherosclerosis, comprising the step of: measuring the level of carbamylated LDL in a sample obtained from said individual. Further provided is a method of reducing carbamylation in an individual in need of such reducing, comprising the step of: treating said individual with a monomeric amino acid or another enzymatic or non-enzymatic inhibitor of carbamylation. Also provided is a method of preventing carbamylation in an individual with normal renal function, comprising the step of: treating said individual with a monomeric amino acid. Further provided is a method of treating or preventing atherosclerosis in an individual in need of such reducing, comprising the step of: inhibiting aggregation and/or deposition of carbamylated LDL in said individual.
    Type: Grant
    Filed: August 27, 2002
    Date of Patent: January 13, 2009
    Assignee: The Board of Trustees of the University of Arkansas
    Inventors: Yousri M. Barri, Sudhir V. Shah, Alexei G. Basnakian
  • Patent number: 7445933
    Abstract: The present invention relates to a stable liquid calibrator or control for use in ligand-binding assays wherein the calibrator or control comprises at least one human synthetic natriuretic peptide and has a pH of from about 4.0 to about 6.5 and remains stable when stored at temperatures of from about 2 to about 8°C. for a period of about twelve months.
    Type: Grant
    Filed: July 16, 2003
    Date of Patent: November 4, 2008
    Assignee: Abbott Laboratories, Inc.
    Inventors: Judith A. Friese, Matthew S. Matias, Ray A. Weigand
  • Patent number: 7432105
    Abstract: A self-calibrated, magnetic binding assay (e.g., sandwich, competitive, etc.) for detecting the presence or quantity of an analyte residing in a test sample is provided. The magnetic binding assay includes detection probes capable of generating a detection signal (e.g., fluorescent non-magnetic particles) and calibration probes capable of generating calibration signal (e.g., fluorescent magnetic particles). The amount of the analyte within the test sample is proportional to the intensity of the detection signal calibrated by the intensity of the calibration signal.
    Type: Grant
    Filed: August 27, 2002
    Date of Patent: October 7, 2008
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Xuedong Song, Rosann Kaylor
  • Patent number: 7390631
    Abstract: Methods for diagnosing and monitoring systemic lupus erythematosus (SLE) or scleroderma by determining, in a blood sample from the individual being diagnosed or monitored, complement component C4d deposited on surfaces of red blood cells in the sample, and optionally also determining complement receptor CR1 deposited on the red blood cell surfaces. For diagnosis this is compared with the quantity of C4d (and optionally CR1) present on red blood cells of normal individuals. For monitoring it is compared with a value in a sample or samples previously obtained from the individual patient. The comparison may be made with individual values for C4d and CR1 and/or with a ratio of the two found in normal individuals.
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: June 24, 2008
    Assignee: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Joseph M. Ahearn, Susan M. Manzi
  • Patent number: 7348157
    Abstract: A method for detection and/or quantification of cardiac troponin I (cTnI) in a sample derived from an individual's blood, the method being based on a sandwich immunoassay employing at least two capture antibodies and at least one tracer antibody, in which a first capture antibody is directed to the N-terminal part of cTnI, to the C-terminal part of cTnI or to the part of the cTnI midfragment, which is slightly affected by the interfering factor, and a second capture antibody is directed to another of these parts, and a tracer antibody is directed to the N-terminal part of cTnI, to the C-terminal part of cTnI or to TnC, which is complexed with cTnI.
    Type: Grant
    Filed: April 7, 2004
    Date of Patent: March 25, 2008
    Assignee: University of Turku
    Inventors: Susann Eriksson, Kim Pettersson
  • Patent number: 7291501
    Abstract: The present invention relates to methods for making stable compositions, such as, but not limited to, test samples, that can be used in ligand-binding assays.
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: November 6, 2007
    Assignee: Abbott Laboratories
    Inventors: Robert G. Parsons, David J. Daghfal, Cherie A. Lipowsky, Ray A. Weigand, Judith A. Friese
  • Patent number: 7288410
    Abstract: Compositions, reagents, kits, systems, system components, and methods for performing assays. More particularly, the invention relates to the use of novel combinations of reagents to provide improved assay performance.
    Type: Grant
    Filed: February 9, 2005
    Date of Patent: October 30, 2007
    Assignee: Meso Scale Technologies, LLC.
    Inventors: Michael Tsionsky, Eli N. Glezer, Selen Altunata, George Sigal, Jonathan K. Leland, Mark A. Billadeau, Svetlana Leytner, Mark Martin, Larry Helms
  • Patent number: 7195923
    Abstract: The present invention provides methods for determining a ratio of an amount of a glycated form of a protein to a total amount of the protein in a sample containing the glycated protein, the glycosylated protein, or the glycoprotein. The method incorporates lateral flow test strip or vertical flow test strip devices having negatively charged carboxyl or carboxylate groups and hydroxyboryl groups immobilized and interspersed on a solid support matrix. The solid support matrix may include derivatives of cellulose (e.g., carboxy cellulose) derivatized with carboxylic acid (e.g., carboxylate, carboxyl) groups and hydroxyboryl compounds including phenylboronic acid (e.g., phenylborate), aminophenylboronic acid, boric acid (e.g., borate), or other boronic acid (e.g., boronate) compounds. The present invention is usefi.il for monitoring glycation or glycosylation of hemoglobin or albumin for monitoring glycemic control (e.g., glycemia in diabetes).
    Type: Grant
    Filed: January 31, 2002
    Date of Patent: March 27, 2007
    Assignee: Scripps Laboratories, Inc.
    Inventors: Ralph P. McCroskey, Cameron E. Melton
  • Patent number: 7166469
    Abstract: A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient.
    Type: Grant
    Filed: June 18, 2002
    Date of Patent: January 23, 2007
    Assignee: Leuven Research & Development VZW
    Inventors: Paul N. Holvoet, Désiré J. Collen
  • Patent number: 7115422
    Abstract: A sample separation apparatus including a porous, or rough, capillary column. The porous capillary column includes a matrix which defines pores, and may be formed rough surface of hemispherical grain silicon. The capillary column is defined in a surface of a substrate, such as silicon. The sample separation apparatus may include a stationary phase or a capture substrate disposed on the surfaces thereof. The sample separation apparatus may also include a detector positioned proximate the capillary column. A variation of the sample separation apparatus includes an electrode proximate each end of the capillary column. The sample separation apparatus may be employed to effect various types of chromatographic separation, electrophoretic separation, and analyte identification.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: October 3, 2006
    Assignee: Micron Technology, Inc.
    Inventor: Terry L. Gilton
  • Patent number: 7109036
    Abstract: A hematology reference control containing an immature granulocyte component and the method of making are disclosed. The reference control includes an immature granulocyte component made of processed blood cells for simulating human immature granulocytes, and a suspension medium suitable for delivering the component to a blood analyzer for measurement of immature granulocytes. The immature granulocyte component can be made of processed avian, reptile or fish red blood cells, or human immature granulocytes produced in vitro. The reference control further includes a white blood cell component which includes white blood cell sub-components for simulating white blood subpopulations. Further disclosed is the method of using the reference control for measurement of immature granulocytes on a blood analyzer.
    Type: Grant
    Filed: May 13, 2004
    Date of Patent: September 19, 2006
    Assignee: Beckman Coulter, Inc.
    Inventors: Nery Ortiz, Theodore J. Gerula, Yi Li
  • Patent number: 7091050
    Abstract: The present invention provides an improved system for detecting the presence or level of an analyte in a sample. In “competition-like” assays of the present invention, a sample including an analyte is mixed with a second ligand to which the analyte binds, and the mixture is exposed to a solid phase containing a first ligand that can compete with the analyte for binding to the second ligand. According to the present invention, the time of exposure of the mixture to the solid phase is limited so that substantially no dissociation of analyte/second ligand complex occurs. The competition-like assays of the present invention are preferably performed with a solid phase containing a substantial excess of first ligand. In “sandwich-type” assays of the present invention, a sample including an analyte is contacted with a solid phase including a first ligand that binds the analyte and, simultaneously or subsequently, is contacted with a second ligand that binds the analyte (or the analyte/first ligand complex).
    Type: Grant
    Filed: October 22, 2003
    Date of Patent: August 15, 2006
    Assignee: Sapidyne Instruments Inc.
    Inventors: Steve J. Lackie, Thomas R. Glass
  • Patent number: 7081347
    Abstract: A method for assessing aspirin resistance and relative risk of a cardiovascular event in a patient taking aspirin is provided. The concentration of 11-dehydro-thromboxane B2 in a urine sample is measured and compared to a set of standardized quartile concentrations. A concentration of urinary 11-dehydro-thromboxane B2 that falls within the second, third, or fourth quartile is indicative of aspirin resistance and an elevated risk of a recurrent cardiovascular event.
    Type: Grant
    Filed: September 24, 2003
    Date of Patent: July 25, 2006
    Assignee: McMaster University
    Inventors: Salim Yusuf, Jack Hirsh, John Eikelboom
  • Patent number: 6951716
    Abstract: Immunoassay methods and apparatus are provided which utilize flow cytometry, coated latex microspheres, and fluorochrome labeled antibodies, to simultaneously detect the presence and amount of one or more analytes in a sample. Beads of several different sizes, colors or shapes, each bead are coated with a different analyte, for the simultaneous detection of one or more analytes and of cell components. The invention is also directed to platelet Ig positive control reagents and assays which provide for the setting of the fluorescence positive region for each patient. The platelet control is sized to fit between the platelets and red cells and thus making it ideal as a true biological control.
    Type: Grant
    Filed: June 6, 2002
    Date of Patent: October 4, 2005
    Inventor: Mark Hechinger
  • Patent number: 6933106
    Abstract: Immunoassay methods and apparatus are provided which utilize flow cytometry, coated latex microspheres, and fluorochrome labeled antibodies, to simultaneously detect the presence and amount of one or more analytes in a sample. By combining FALS and fluorescence, it is practical to use beads of several different sizes, colors or shapes, each bead coated with a different analyte, for the simultaneous detection of one or more analytes and of cell components such as platelets in a sample.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: August 23, 2005
    Inventor: Mark Hechinger
  • Patent number: 6927062
    Abstract: Controls and standards for assays and method for manufacturing the controls and standards is described. The controls or standards comprise a porous carrier material which has quantitatively reversibly absorbed and dried thereon an analyte for the control or standard wherein the analyte is not degraded over time while it is absorbed to the porous carrier material. Preferably, the controls and standards are provided as a control strip (10) in which the porous carrier material (20) is adhered to the distal end (16) of a support member (12). To quantitatively elute the analyte from the carrier to a solvent for an assay, the carrier is contacted to the same solvent used for the samples in the assay. After the analyte has been eluted, the carrier is discarded and the assay is performed. The controls and standards are useful for assays which detect bacteria, fungi, viruses, and proteins.
    Type: Grant
    Filed: November 25, 2002
    Date of Patent: August 9, 2005
    Assignee: Agdia, Inc.
    Inventor: Barbara A. Schoedel
  • Patent number: 6867011
    Abstract: The invention relates to synthetic biepitope compounds which can be used as standards in immunoassays, for the assay of troponin I, method for preparing them, compositions and kits containing such compounds as well as the immunoassay methods using such compounds.
    Type: Grant
    Filed: December 4, 1997
    Date of Patent: March 15, 2005
    Assignee: Bio-Rad Pasteur
    Inventors: Fabienne Noelle Babin, Charles Didier Calzolari, Odile Suzanne Helene Flecheux, Claude Granier, Catherine Christiane Marie Larue, Bernard Christian Pau, Francois Yves Rieunier, Sylvie Marie-France Trinquier
  • Patent number: 6767708
    Abstract: Aqueous solutions of steroid compounds which have biological activity and have a tendency to oxidative degradation at temperatures between 2 and 8° C. on storage in excess of several months are stabilized by the addition of chelators. Aqueous solutions of particular interest are protein containing solutions which mimic the behavior of human bodily fluids such as serum and are therefore suitable as standards for immunoassays for steroids in such bodily fluids. Chelators of particular interest are transition metal chelators especially those which efficiently sequester iron.
    Type: Grant
    Filed: December 8, 1995
    Date of Patent: July 27, 2004
    Assignee: Abbott Laboratories
    Inventors: Gregg T. Williams, Hoda I. Aboleneen, William R. Groskopf, Steven C. Kuemmerle
  • Patent number: 6746848
    Abstract: A method for quantitating cellular proteins in tissue, by means of a cell imaging densitometer in conjunction with immunohistological staining and a reference standard, is provided. Unlike prior art methods, which provide ordinal measures of relative amounts of protein among different cells, the method enables the quantitation of antigenic proteins in terms of absolute mass of protein/tumor or protein/patient, molecules of protein per cell, and volume or fraction of a tissue sample expressing the protein of interest. The method is useful for research purposes in the study of protein expression, and is shown to improve the accuracy of clinical histopathological analysis of tumor tissue sections for diagnosis and prognosis. The method is expected to be useful for prescribing in situ treatment dosages.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: June 8, 2004
    Inventor: Steven Jay Smith
  • Patent number: 6740527
    Abstract: Cyanide-free reagents for the determination of hemoglobin and leukocytes present in a blood sample comprise an aqueous solutions of at least one quaternary ammonium salt, preferably selected from the group of alkyltrimethylammonium salts, alkyldimethylbenzylammonium salts or alkylpyridium salts consisting of tetradecyltrimethyl ammonium bromide (TTAB), dodecyltrimethyl ammonium chloride, cetyltrimethyl ammonium bromide, hexadecyltrimethyl ammonium bromide and benzalkonium chlorides, and hydroxylamine salts, especially hydrochloride, sulfate and phosphates and other acid salts. The method involves mixing the reagent with a diluent-diluted blood sample, presenting it to an absorbance spectrophotometer and measuring the resulting optical density as an indicator of hemoglobin concentration. This cyanide-free reagent could be used solely for hemoglobin determinations, or, it can also be used in leukocyte counting and sizing using hematology instrumentation.
    Type: Grant
    Filed: May 27, 1997
    Date of Patent: May 25, 2004
    Assignee: Abbott Laboratories
    Inventors: Show-Chu Wong, Sylvia Khoo
  • Patent number: 6686170
    Abstract: The present invention relates to an improved immunoassay device for confirming the validity of a test result showing either the presence or absence of an analyte in a patient sample. In the improved device, control reagents are provided in the device which directly mimic the reaction of the sample analyte with the test reagents of the device. The device thus allows the user to verify the efficacy of the test reagents at all stages of interaction with the sample analyte.
    Type: Grant
    Filed: August 17, 1994
    Date of Patent: February 3, 2004
    Assignee: Abbott Laboratories
    Inventors: Richard T. Flanders, Vincent A. Varitek, Jr.
  • Patent number: 6664070
    Abstract: A washing solution for solid-phase immunometric methods which contains stabilizers for the labeling system, and the use thereof
    Type: Grant
    Filed: February 14, 1994
    Date of Patent: December 16, 2003
    Assignee: Dade Behring Marburg GmbH
    Inventor: Hans-Detlef Dopatka
  • Patent number: 6664114
    Abstract: The present invention provides an improved system for detecting the presence or level of an analyte in a sample. In “competition-like” assays of the present invention, a sample including an analyte is mixed with a second ligand to which the analyte binds, and the mixture is exposed to a solid phase containing a first ligand that can compete with the analyte for binding to the second ligand. According to the present invention, the time of exposure of the mixture to the solid phase is limited so that substantially no dissociation of analyte/second ligand complex occurs. The competition-like assays of the present invention are preferably performed with a solid phase containing a substantial excess of first ligand.
    Type: Grant
    Filed: July 18, 1994
    Date of Patent: December 16, 2003
    Assignee: Sapidyne Instruments, Inc.
    Inventors: Steve J. Lackie, Thomas R. Glass
  • Patent number: 6653066
    Abstract: Disclosed is a device and method of use for detecting polyvalent analytes such as antibody to the AIDS virus, utilizing an inverse sandwich method. The test device comprises a first substance having an epitope, bound to a label and capable of moving within the test device. The test device further comprises a second substance immobilized to the test device and spatially separated from the first substance. The second substance has an epitope substantially similar to the epitope of the first substance. Upon application to the test device, the polyvalent analyte binds to the first substance and moves within the test device to the location of the second substance with both polyvalent analyte and first substance are immobilized at location of the second substance. Polyvalent analyte is detected by the presence of the label at the location of the second substance. Also disclosed is a control substance for use with the device that can be used to determine completion of the test and viability of the device.
    Type: Grant
    Filed: June 17, 1994
    Date of Patent: November 25, 2003
    Assignee: Trinity Biotech
    Inventor: Siegfried R. Krutzik